GlobeNewswire

Orange Polska and Orange Belgium Partner with Salesforce and Vlocity to Strengthen Their Digital Transformation

Dela

WARSAW, Poland and BRUSSELS, Belgium and SAN FRANCISCO, March 28, 2018 (GLOBE NEWSWIRE) -- Orange Polska and Orange Belgium announced today that they signed an agreement with Salesforce, the global leader in CRM, and Vlocity, a leading industry cloud company. Salesforce and Vlocity will help Orange achieve business agility faster and reduce time to market by leveraging cloud-based solutions across Orange's digital and assisted channels.

Given today's digital landscape, it's become imperative for Orange to strengthen its position in mobile and convergence markets with a customer-centric focus. Thanks to the expertise of Salesforce and Vlocity, Orange can further improve the quality of its customer experience by introducing a robust omnichannel experience for its customers. In addition, Orange sales teams and channel partners will be able to sell new innovative products and services smarter, helping them go the extra mile for Orange customers.

Orange Polska takes a significant step in its digital transformation

"Orange Polska is moving a step further in its digital transformation. Having reached a significant level of consolidation of its digital and sales channels, Orange Polska now targets to offer a differentiating customer experience." said Jean-François Fallacher, CEO of Orange Polska. "We choose Vlocity and Salesforce for their deployment speed but also for their advanced products and journey management capabilities. This partnership will enable us to meet our customers' expectations for simple, transparent, easy-to-use and easy-to-manage offers. Innovation and customer experience are significant cornerstones of the Orange strategy."

Orange Belgium continues to digitalize the Orange customer journey

"Orange Belgium continues its digital transformation. Next to renewing certain levels of our order management, we will now start strengthening our CRM capabilities and unifying our digital channels. In this perspective, we partnered up with Vlocity and Salesforce," said Michaël Trabbia, CEO of Orange Belgium. "We chose Salesforce and Vlocity because they demonstrate advantages on multiple fronts, including speed to deployment, accelerated time-to-market and streamlined service delivery. This collaboration will indeed enable us to further digitize our customer journey and to be even more relevant for our customers, who remain at the heart of the Orange Belgium strategy."

Salesforce and Vlocity empower Orange to fully engage in digital transformation

"By embracing the cloud, Orange has taken an important step in its core mission to achieve outstanding customer connectivity and make its services easier to access and sell," said Jo Buvens, Country Manager Salesforce Belgium and Luxembourg. "We're thrilled to be working with Vlocity on this important project. By leveraging Vlocity's industry specific cloud solutions and omnichannel applications, Orange can now fully engage in its digital transformation."

"We're incredibly excited about this opportunity to join forces with Salesforce to provide Orange with the industry-focused digital software that they need to transform the way they do business," said Dominic Dinardo, EVP and Managing Director EMEA, Vlocity. "We're thrilled to be selected as Orange's digital transformation technology and look forward to helping Orange capture more value from the cloud, reach more customers, sell smarter and sell more efficiently."

Vlocity Communications takes advantage of the omnichannel capabilities of Salesforce Service Cloud and includes comprehensive Enterprise Product Catalog, CPQ (Configure-Price-Quote), Contract Management, Retail Clienteling and Order Management functionality, and a comprehensive library of pre-built sales, service and billing inquiry management processes. Engineered specifically for communications service providers, Vlocity Communications conforms to TM Forum industry standards, and integrates flexibly with third-party systems through pre-built APIs and web services. For more information on Vlocity Communications, please click here.

Salesforce and others are among the trademarks of salesforce.com , inc.

About Vlocity
Vlocity, a Forbes Cloud 100 company and strategic Salesforce ISV, delivers industry-specific cloud and mobile software that embed digital, omnichannel processes for customer-centric industries. Built in partnership with Salesforce, the world's #1 CRM company, Vlocity is one of Salesforce's fastest growing partners. Vlocity Industry Cloud Apps embed industry-specific functionality, best practices and business processes for the Communications & Media, Insurance & Financial Services, Health Insurance, Energy and Public Sector industries. Vlocity enables companies to achieve faster business agility and time to value from the cloud across digital and traditional channels. Learn more at www.vlocity.com and follow us at @vlocity.

About Orange Polska
Orange Polska is Poland's leading telecommunication provider, operating in all segments of the telecom market. We have the largest technical infrastructure in Poland, enabling us to provide services and convergent offers based on cutting-edge technologies, including fiber internet, 4G/LTE mobile data transmission and 4K TV. We invest intensely in both mobile and fixed networks, our ambition is to cover more than 5 million households in Poland with fiber by the end of 2020. Our mobile 4G/LTE network now covers almost the entire population of Poland. Orange Polska is one of the most socially committed companies in the country. The programs of Orange Foundation counteract digital exclusion and develop digital skills. 
Orange Polska is listed on the Warsaw Stock Exchange. We are part of the global Orange Group.

More information on: https://www.orange.pl; follow us on Twitter: @ Orange_Polska

About Orange Belgium
Orange Belgium is one of the leading telecommunication operators on the Belgian market, with over 3 million customers, and in Luxembourg through its subsidiary Orange Communications Luxembourg. As a convergent actor, we provide mobile telecommunication services, internet and TV to private clients, as well as innovative mobile and fixed line services to businesses. Our high-performance mobile network supports 2G, 3G, 4G and 4G+ technology and is the subject of ongoing investments.  Orange Belgium is a subsidiary of the Orange Group, one of the leading European and African operators for mobile telephony and internet access, as well as one of the world leaders for telecommunication services to enterprises. Orange Belgium is listed on the Brussels Stock Exchange (OBEL). More information on: corporate.orange.bewww.orange.be  or follow us on Twitter : @pressOrangeBe.

Press Contacts

Orange Polska
Wojciech Jabczynski - wojciech.jabczynski@orange.com

Orange Belgium
Annelore Marynissen - annelore.marynissen@orange.com  -  +32 (0) 479 01 60 58
Jean-Pascal Bouillon - jean-pascal.bouillon@orange.com  -  +32 (0) 473 94 87 31
press@orange.be

Contact investors
Siddy Jobe - ir@orange.be - +32(0)2 745 80 92

Vlocity
Bhava Communications for Vlocity
Rachel Austin
vlocity@bhavacom.com
979-324-7905




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vlocity via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum